#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Development of chronic myeloid leukaemia treatment over the past 25 years


Authors: E. Faber;  K. Indrák
Authors‘ workplace: Hemato-onkologická klinika FN a LF UP v Olomouci
Published in: Transfuze Hematol. dnes,25, 2019, No. 1, p. 118-124.
Category: Review/Educational Papers

Overview

Introduction of tyrosine kinase inhibitors into the treatment of chronic myeloid leukaemia (CML) over the past 25 years has resulted in a revolutionary change and has had a crucial impact on global treatment strategies in oncology. CML has been transformed from a deadly malignancy into a chronic disorder with patients today dying more frequently from other illnesses and patient overall survival equalling that of the general population. As treatment efficacy rises, prevention and management of side effects is of growing importance. The logical next step is an attempt to stop treatment in optimally responding patients with the aim of maintaining treatment-free remission. On the other hand, a small fraction of high-risk patients can still profit from bone marrow transplantation and these patients may profit prospectively from the introduction of new classes of inhibitors acting outside the ABL kinase domain. Cure of CML with targeted conservative treatment has become the long-term aim. This review discusses the developments in CML treatment over the past 25 years with emphasis on the Czech contribution.

Keywords:

chronic myeloid leukaemia – Tyrosine kinase inhibitors – interferon alpha


Sources

1. Carella AM, Lerma E, Celesti L, et al. Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. Br J Haematol 1998;100:445–448.

2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.

3. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112(13):309–318.

4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.

5. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.

6. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001;293:876–880.

7. Naušová J, Priwitzerová M, Jarošová M, et al. Chronická myeloidní leukémie - rezistence na imatinib mesylát (Glivecâ) (Přehled literatury a vlastní zkušenosti). Čas Lék Čes 2006;145:377–382.

8. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259.

9. Hochhaus A, Mahon FX, le Coutre P et al. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. J Cancer Res Clin Oncol 2017;143:1225–1233.

10. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.

11. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207–3213.

12. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6):2303–2309.

13. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007;109:5143–5150.

14. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.

15. Cortes J, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30(28):3486–3492.

16. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783–1796.

17. Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:612–621.

18. Hehlmann R. Ann Hematol 2015;94(Suppl 2):S103–S105.

19. Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374–2386.

20. Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011; 29:2514–2520.

21. Saussele S, Krauss MP, Hehlmann R et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015 Jul 2;126(1):42–49.

22. Steegmann JL, Baccarani M, BrecciaM et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016;30:1648–1671.

23. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19:747–757.

24. Šrámek J, Karas M, Lysák D, Jindra P. Možnost ukončení terapie tyrosin kinázovými inhibitory u nemocných s chronickou myeloidní leukemií a koncept „treatment-free remission“. Transfuze Hematol dnes 2017;23(4):192–198.

25. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of The European LeukemiaNet. Blood 2006;108:1809–1820.

26. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.

27. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 2017;31:593–601.

28. Soverini S, Hochhaus A, Nicolini FE et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:1208–1215.

29. Cross NC, White HE, Ernst T, et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia 2016;30(9):1844–1852.

30. Faber E, Naušová J, Jarošová M, et al. Intermittent dosage of imatinib mesylate in CML patients with history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 2006;47:1082–1090.

31. Klamova H, Faber E, Zackova D, et al. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma 2010;57:355–359.

32. Faber E, Mojzikova R, Plachy R, et al. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL1 kinase domain mutation. Leuk Res 2010;34:91–93.

33. Zackova D, Klamova H, Dusek L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? Amer J Hematol. 2011;86:318–321.

34. Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperative centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry. Eur J Haematol 2011;87:157–168.

35. Voglová J, Mužík J, Faber E, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011;58:256–262.

36. Zackova D, Klamova H, Muzik J, et al. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Leuk Lymphoma 2013;54(10):2310–2313.

37. Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013;98(10):e124–126.

38. Pavlik T, Janousova E, Mayer J, et al. Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications. Am J Hematol 2013;88(9):790–797.

39. Faber E, Divoká M, Skoumalová I, et al. Lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma 2016;57(2):370375.

40. Faber E, Friedecký D, Mičová K, et al. Imatinib trough plasma
levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 2012;91:923929.

41. Racil Z, Razga , Klamova H, et al. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematol Oncol 2013;32(2):331–334.

42. Jaruskova M, Curik N, Hercog R, et al. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res 2017;36(1):55.

43. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19(6):747-757.

44. Saglio G, Sharf G, Almeida A, et al. Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective. Clin Lymphoma Myeloma Leuk 2018;18(6):375-379.

45. Faber E, Hluší A, Indrák K, et al. Imatinib (Glivec®) v léčbě nemocných s akcelerovanou fází chronické myeloidní leukémie a Ph pozitivní akutní lymfoblastické leukémie. Transfuze Hematol dnes 2003;9:159–165.

46. Voglová J, Poznarová A, Chrobák L, et al. Imatinib mesylát (Glivec®) v léčbě chronické fáze chronické myeloidní leukémie. Vnitř Lék 2004;50:21–29.

47. Klamova H, Voglova J. Chronická myeloidní leukemie. Transfuze Hematol dnes 2010;16:17–20.

48. Mayer J,  Brychtová Y,  Doubek M,  Krejčí M,  Vorlíček J. Srovnání reálné ceny léčby chronické myeloidní leukemie nemyeloablativní transplantací krvetvorných buněk s hypotetickou terapií imatinibem (Glivec). Zamyšlení nad velmi drahými medicínskými postupy. Transfuze Hematol dnes 2006;12(1):6–13.

49. Mayer J,  Klamová H,  Žáčková D, et al. Rezistence na imatinib a možnosti využití vyššího dávkování léku u pacientů s chronickou myeloidní leukemií. Transfuze a Hematol dnes 2007;13(3):133–141.

50. Rohoň P, Faber E, Naušová J, et al. Od monitorovania hladiny fúzneho génu Bcr/Abl u pacienta s chronickou myeloidnou leukémiouodhaľovaniu príčiny rezistencie k imatinibu – kazuistika. Transfuze Hematol dnes 2007;13(1):27–31.

51. Mayer J,  Klamová H,  Žáčková D, et al. Imatinib v první linii léčby nemocných s nově diagnostikovanou chronickou myeloidní leukemií v chronické fázi. Transfuze Hematol dnes 2008;14(4):150–158.

52. Rohoň P, Rožmanová Š, Zapletalová J, et al. Výsledky liečby pacientovchronickej fáze chronickej myelocytovej leukémie na HOK v Olomouci v rokoch 2000-2009: prognostický význam Sokalovho indexu a ELN kritérií. Transfuze a hematol dnes 2010;16(4):202–209.

53. Šťastný M, Machová Poláková K, Klamová H, et al. Analýza mutací BCR-ABL u CML pacientů rezistentních k imatinibu umožňuje poskytnout „terapii šitou na míru“. Transfuze Hematol dnes 2010;16(1):47–54.

54. Rožmanová Š, Rohoň P, Divoká M, et al. Hodnocení časné molekulární odpovědi po 3 měsících léčby imatinibem může u nemocných s chronickou myeloidní leukemií přispět k upřesnění odhadu prognózy – zkušenosti jednoho centra. Transfuze Hematol dnes 2012;18(2):66–71.

55. Martišová M, Sninská Z, Hatalová A, Demečková E, Mistrík M. Dasatinib v 2. línii liečby chronickej myelocytovej leukémie u pacientovrezistenciou alebo intoleranciou imatinibu na Klinike hematológietransfuziológie Bratislava v rokoch 2007-2011. Transfuze Hematol dnes 2012;18(3):105–111.

56. Zemanová K, Žižková H, Jurček T, et al. Chronická myeloidní leukémie – standardizace molekulárního monitorování hladiny transkriptů BCR-ABL1 v České republice. Transfuze Hematol dnes 2016; 22(1):56–64.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 1

2019 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#